OBJECTIVES: To characterise neonatal hospital drug use and to compare the availability of drug information between Estonian Summaries of Product Characteristics (SPCs) and other sources. STUDY DESIGN: This was a prospective cohort study in which pharmacotherapy information on neonates admitted to Tartu University Clinics between 1 February and 1 August 2008 and to Tallinn Children's Hospital between 1 February and 1 August 2009 was collected. Drug labelling status was determined according to Estonian SPCs, and neonatal information was compared with the British National Formulary for Children (BNFC) and the Thomson Micromedex database. RESULTS: Of 490 hospitalised neonates, 71% received pharmacotherapy. Within the entire study period, there were 1981 prescriptions for 115 products, with a median of four (interquartile range 2-7) products per child. Antibacterial, cardiovascular and central nervous system drugs were the most commonly prescribed. All treated preterm neonates received at least one unlicensed or age-related off-label prescription. All prescriptions for alimentary, genitourinary, musculoskeletal and sensory system drugs were off-label. There were large differences in the neonatal information provided by the different sources, with the largest differences found for term neonates, for whom the information was available for 67, 38 and 24% of prescriptions according to the BNFC, Micromedex and Estonian SPC, respectively. CONCLUSIONS: The high rate of age-related off-label prescribing for neonates calls for urgent action from medical professionals and others to reinforce effective and safe pharmacotherapy for this age group. The existing SPCs should be regularly updated and more closely harmonised to each other.
OBJECTIVES: To characterise neonatal hospital drug use and to compare the availability of drug information between Estonian Summaries of Product Characteristics (SPCs) and other sources. STUDY DESIGN: This was a prospective cohort study in which pharmacotherapy information on neonates admitted to Tartu University Clinics between 1 February and 1 August 2008 and to Tallinn Children's Hospital between 1 February and 1 August 2009 was collected. Drug labelling status was determined according to Estonian SPCs, and neonatal information was compared with the British National Formulary for Children (BNFC) and the Thomson Micromedex database. RESULTS: Of 490 hospitalised neonates, 71% received pharmacotherapy. Within the entire study period, there were 1981 prescriptions for 115 products, with a median of four (interquartile range 2-7) products per child. Antibacterial, cardiovascular and central nervous system drugs were the most commonly prescribed. All treated preterm neonates received at least one unlicensed or age-related off-label prescription. All prescriptions for alimentary, genitourinary, musculoskeletal and sensory system drugs were off-label. There were large differences in the neonatal information provided by the different sources, with the largest differences found for term neonates, for whom the information was available for 67, 38 and 24% of prescriptions according to the BNFC, Micromedex and Estonian SPC, respectively. CONCLUSIONS: The high rate of age-related off-label prescribing for neonates calls for urgent action from medical professionals and others to reinforce effective and safe pharmacotherapy for this age group. The existing SPCs should be regularly updated and more closely harmonised to each other.
Authors: Daniel K Benjamin; Philip Brian Smith; M Dianne Murphy; Rosemary Roberts; Lisa Mathis; Debbie Avant; Robert M Califf; Jennifer S Li Journal: JAMA Date: 2006-09-13 Impact factor: 56.272
Authors: A Ceci; M Felisi; P Baiardi; F Bonifazi; M Catapano; C Giaquinto; A Nicolosi; M Sturkenboom; A Neubert; I Wong Journal: Eur J Clin Pharmacol Date: 2006-10-05 Impact factor: 2.953
Authors: Antje Neubert; Ian C K Wong; Alessandro Bonifazi; Mariana Catapano; Mariagrazia Felisi; Paola Baiardi; Carlo Giaquinto; Catherijne A J Knibbe; Miriam C J M Sturkenboom; Maisoon A Ghaleb; Adriana Ceci Journal: Pharmacol Res Date: 2008-09-18 Impact factor: 7.658
Authors: L Lindell-Osuagwu; M J Korhonen; S Saano; M Helin-Tanninen; T Naaranlahti; H Kokki Journal: J Clin Pharm Ther Date: 2009-06 Impact factor: 2.512
Authors: Giovanni Tafuri; Francesco Trotta; Hubert G M Leufkens; Nello Martini; Luciano Sagliocca; Giuseppe Traversa Journal: Eur J Clin Pharmacol Date: 2008-09-17 Impact factor: 2.953
Authors: Adriana Cristina de Souza Gonçalves; Adriano Max Moreira Reis; Ana Carolina Marçal Gusmão; Maria Cândida Ferrarez Bouzada Journal: Int J Clin Pharm Date: 2015-04-02
Authors: Georgi Nellis; Tuuli Metsvaht; Heili Varendi; Jana Lass; Jennifer Duncan; Anthony J Nunn; Mark A Turner; Irja Lutsar Journal: Paediatr Drugs Date: 2016-06 Impact factor: 3.022